Aurinia Pharmaceuticals Inc. (AUPH) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Edmonton, BC, Canada. The current CEO is Kevin C. Tang.
AUPH has IPO date of 2014-09-03, 130 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $2.14B.
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
